Hyperion Therapeutics Grants Rights to Sobi to Distribute RAVICTI in Middle East

SwedishOrphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Hyperion Therapeutics(NASDAQ: HPTX) announced today that Sobi has been granted the exclusive rightsby Hyperion to distribute RAVICTI (glycerol phenylbutyrate) Oral Liquid on anamed patient basis for the chronic treatment of Urea Cycle Disorders (UCD) inthe Middle East. Under the agreement, Sobi receives the rights to provideRAVICTI in Saudi Arabia, Oman, United Arab Emirates, Jordan, Kuwait, Qatar andBahrain. Financial details were not disclosed."We are proud of this partnership with Hyperion and RAVICTI is a perfect fitwith our existing UCD business and the capabilities within our GeneticsTherapeutic Area," said Geoffrey McDonough, President and CEO at Sobi. "Webelieve the recent FDA approval of RAVICTI can allow us to provide access forthis important therapy in the Middle East."UCD patients lack enzymes or transporters necessary for the conversion ofammonia to urea and experience heightened levels of ammonia in the bloodstream.Left untreated, UCDs can result in neurological damage, coma, and/or death.Approved by the Food and Drug Administration on February 1, 2013, RAVICTI is anoral medication used for the long-term management of high blood levels ofammonia.- - -About RAVICTIIn short term clinical studies involving more See full press release